Vol. 18/No. 13 | OncologyLive

Nanotech Remains a Robust Research Focus

July 07, 2017

The nanotechnology sector has had its share of disappointments in the arena of oncology therapeutics. Nevertheless, the FDA is reviewing a new drug application for a novel compound and numerous investigational agents are in the pipeline.

"Trojan Horse" Tested in EGFR-Amplified Glioblastoma

July 06, 2017

Investigators are seeking to determine whether the addition of ABT-414 to concomitant radiotherapy and temozolomide will improve the survival of patients with newly diagnosed glioblastoma multiforme with EGFR amplification.

Sequencing Strategies Advance Care Amid Challenges in Pancreatic Cancer

July 05, 2017

Recent developments in the treatment of metastatic pancreatic cancer have modestly improved outcomes, but reducing morbidities associated with current therapies and developing novel therapeutics will be essential for achieving durable responses and long-term survival.

Informed Patients Are More Likely to Choose Palliative Care

July 03, 2017

Research from Tulane University provides a strong case that, across demographic and clinical populations, informed patients are less wary of palliative care and more inclined to take advantage of the favorable effects that palliative care services can offer for patient-centered outcomes.

VCU Explores Novel Combos for Solid Tumors

July 03, 2017

Studies conducted at VCU Massey Cancer Center in Richmond, Virginia, over the past 7 years have developed the therapeutic combination of pemetrexed and sorafenib (Nexavar) from the bench to the bedside, and now into phase II clinical trial evaluation.

From Bench to Bedside: O'Shaughnessy Keeps Patients in Focus

July 02, 2017

Joyce A. O'Shaughnessy, MD, whose research helped establish capecitabine and gemcitabine as treatments for patients with breast cancer, was honored in the Community Outreach/Education category with a 2016 Giants of Cancer Care® award, a program that OncLive® developed to recognize leaders in the field.